Profile data is unavailable for this security.
About the company
Atara Biotherapeutics, Inc. is an allogeneic T-cell immunotherapy company. The Company is a developer of T-cell immunotherapy, leveraging its novel allogeneic Epstein-Barr virus (EBV) T-cell platform to develop transformative therapies for patients with serious diseases, including solid tumors, hematologic cancers, and autoimmune diseases. Its pipeline products include Ebvallo (Tab-cel), ATA3219. The Company’s T-cell immunotherapy, tab-cel (tabelecleucel), is in Phase III development for patients with EBV-driven post-transplant lymphoproliferative disease (EBV+ PTLD) who have failed rituximab or rituximab plus chemotherapy, as well as other EBV-driven diseases. Its ATA3219 is in Phase 1 development is being developed as a potential product intended to target B-cell malignancies and autoimmune diseases, based on a next generation 1XX co-stimulatory domain and the innate advantages of EBV T cells as the foundation for an allogeneic CAR T platform.
- Revenue in USD (TTM)8.57m
- Net income in USD-276.13m
- Incorporated2012
- Employees225.00
- LocationAtara Biotherapeutics Inc2380 Conejo Spectrum St, Suite 200THOUSAND OAKS 91320United StatesUSA
- Phone+1 (805) 623-4244
- Fax+1 (302) 636-5454
- Websitehttps://www.atarabio.com/
Peer analysis
- Key Information
- Stock Performance
- Per Share Data
- Efficiency
- Management Effectiveness
- Profitability
- Financial Strength
- Growth Rates
Company | Revenue (TTM) | Net income (TTM) | Market cap | Employees | Price/earnings (TTM) | Price/book value (MRQ) | Price/cash flow (TTM) | Price/sales (TTM) | EPS (excl. extraordinary items, TTM) | EPS (incl. extraordinary items, TTM) | Revenue per share (TTM) | Book value per share (MRQ) | Asset turnover (TTM) | Inventory turnover (TTM) | Receivables turnover (TTM) | Revenues per employee (TTM) | Return on avg assets (TTM) | Return on avg assets (5 yr avg) | Return on investment (TTM) | Return on investment (5 yr avg) | Gross margin (TTM) | Gross margin (5 yr avg) | Net profit margin (TTM) | Net Profit margin (5 yr avg) | Quick ratio (MRQ) | Interest coverage (TTM) | Total debt to capital (MRQ) | Payout ratio (5 yr avg) | Revenue (YOY change %) | Revenue (5 yr growth rate) | Net income (YOY change %) | Net income (5 yr growth rate) | Capital expenditure (5 yr growth rate) | Dividend (5 yr growth rate) |
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Anebulo Pharmaceuticals Inc | 0.00 | -10.49m | 76.50m | 2.00 | -- | 11.79 | -- | -- | -0.4087 | -0.4087 | 0.00 | 0.2502 | 0.00 | -- | -- | 0.00 | -86.04 | -- | -95.37 | -- | -- | -- | -- | -- | -- | -- | 0.00 | -- | -- | -- | -71.89 | -- | -- | -- |
Cognition Therapeutics Inc | 0.00 | -25.79m | 77.28m | 25.00 | -- | 2.54 | -- | -- | -0.8564 | -0.8564 | 0.00 | 0.7609 | 0.00 | -- | -- | 0.00 | -60.26 | -- | -76.27 | -- | -- | -- | -- | -- | -- | -1,878.67 | 0.00 | -- | -- | -- | -20.52 | -- | -- | -- |
Alpha Teknova Inc | 36.68m | -36.78m | 77.56m | 210.00 | -- | 0.8609 | -- | 2.11 | -1.17 | -1.17 | 1.15 | 2.21 | 0.2612 | 2.21 | 8.94 | 174,685.70 | -26.19 | -- | -28.17 | -- | 28.07 | -- | -100.26 | -- | 3.84 | -37.45 | 0.1283 | -- | -11.43 | -- | 22.52 | -- | -- | -- |
Personalis Inc | 73.48m | -108.30m | 78.86m | 223.00 | -- | 0.6006 | -- | 1.07 | -2.25 | -2.25 | 1.53 | 2.56 | 0.2838 | 5.80 | 4.28 | 329,511.20 | -41.83 | -28.84 | -49.51 | -34.72 | 24.78 | 28.65 | -147.38 | -96.01 | 2.89 | -- | 0.0218 | -- | 12.97 | 14.23 | 4.43 | -- | 6.80 | -- |
LAVA Therapeutics NV | 6.77m | -41.97m | 79.66m | 37.00 | -- | 1.56 | -- | 11.77 | -1.58 | -1.58 | 0.2532 | 1.95 | 0.0552 | -- | 2.87 | 182,946.00 | -34.25 | -- | -40.31 | -- | 48.56 | -- | -620.09 | -- | -- | -- | 0.1098 | -- | -65.09 | -- | -31.55 | -- | -- | -- |
Atara Biotherapeutics Inc | 8.57m | -276.13m | 80.68m | 225.00 | -- | -- | -- | 9.41 | -2.61 | -2.61 | 0.0810 | -0.9322 | 0.0316 | 1.57 | 0.2307 | 38,102.22 | -101.91 | -70.20 | -172.16 | -86.94 | -3.65 | -- | -3,220.88 | -1,559.33 | 0.648 | -- | -- | -- | -86.51 | -- | -20.95 | -- | -49.14 | -- |
Passage Bio Inc | 0.00 | -102.06m | 80.71m | 58.00 | -- | 0.6468 | -- | -- | -1.87 | -1.87 | 0.00 | 2.03 | 0.00 | -- | -- | 0.00 | -51.80 | -48.56 | -56.80 | -52.09 | -- | -- | -- | -- | -- | -- | 0.00 | -- | -- | -- | 25.02 | -- | -43.53 | -- |
Provectus Biopharmaceuticals Inc | 557.71k | -3.10m | 80.99m | 4.00 | -- | -- | -- | 145.22 | -0.0074 | -0.0074 | 0.0013 | -0.0181 | 0.32 | -- | 1,282.09 | 139,427.50 | -177.95 | -276.33 | -- | -- | -- | -- | -556.16 | -1,667.76 | -- | -13.22 | -- | -- | -43.61 | -- | 12.74 | -- | -- | -- |
Tempest Therapeutics Inc | 0.00 | -29.49m | 81.98m | 17.00 | -- | 3.04 | -- | -- | -1.96 | -1.96 | 0.00 | 1.21 | 0.00 | -- | -- | 0.00 | -60.38 | -57.10 | -72.81 | -71.20 | -- | -- | -- | -- | -- | -87.30 | 0.2827 | -- | -- | -- | 17.41 | -- | 36.40 | -- |
Marinus Pharmaceuticals Inc | 30.99m | -141.41m | 82.95m | 165.00 | -- | 4.92 | -- | 2.68 | -2.63 | -2.63 | 0.5766 | 0.3072 | 0.144 | 1.55 | 6.11 | 187,812.10 | -65.70 | -49.64 | -77.53 | -57.76 | 93.76 | -- | -456.31 | -518.96 | 4.01 | -14.97 | 0.8132 | -- | 21.63 | -- | -613.59 | -- | 7.47 | -- |
LifeVantage Corp | 205.45m | 3.60m | 83.44m | 248.00 | 23.31 | 3.11 | 11.47 | 0.4061 | 0.2818 | 0.2818 | 16.01 | 2.11 | 3.20 | 2.53 | 91.56 | 828,443.60 | 5.60 | 11.65 | 8.51 | 18.92 | 79.32 | 82.20 | 1.75 | 3.42 | 1.01 | -- | 0.00 | 5.23 | 3.41 | 0.9838 | -18.59 | -18.77 | -7.98 | -- |
Holder | Shares | % Held |
---|---|---|
EcoR1 Capital, LLCas of 31 Dec 2023 | 10.07m | 7.79% |
Redmile Group LLCas of 31 Dec 2023 | 9.11m | 7.05% |
The Vanguard Group, Inc.as of 31 Dec 2023 | 6.59m | 5.10% |
Citadel Advisors LLCas of 08 Mar 2024 | 6.53m | 5.06% |
BlackRock Fund Advisorsas of 31 Dec 2023 | 6.38m | 4.94% |
UBS Securities LLCas of 31 Dec 2023 | 3.69m | 2.86% |
AQR Capital Management LLCas of 31 Dec 2023 | 2.93m | 2.27% |
Millennium Management LLCas of 31 Dec 2023 | 2.92m | 2.26% |
SSgA Funds Management, Inc.as of 31 Dec 2023 | 2.78m | 2.16% |
Geode Capital Management LLCas of 31 Dec 2023 | 2.15m | 1.66% |